CPI-613
Drug timelines are a Plus or Pro feature.
14 regulatory and trial events tracked for CPI-613, covering 2016-12-29 to 2026-03-27. Get the full timeline:
Most recent: Clinical Trial Update: A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations [Phase 2]